Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

587
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
587
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

195
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
195
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

689
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
689
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

868
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
868
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

248
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
248

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric Clinician Adherence to Peanut Allergy Prevention Guidelines: A Randomized Trial.

Pediatrics·2025
Same author

Percent Body Fat and Weight Status of Youth Participating in Pediatric Weight Management Programs in the Pediatric Obesity Weight Evaluation Registry.

Childhood obesity (Print)·2024
Same author

Scoping Review of Pediatric Primary Care Educational Literature.

Clinical pediatrics·2024
Same author

Design of the Intervention to Reduce Early Peanut Allergy in Children (iREACH): A practice-based clinical trial.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2024
Same author

Diabetes screening outcomes in youth presenting for paediatric weight management: A report of the Paediatric Obesity Weight Evaluation Registry.

Pediatric obesity·2024
Same author

Exploring Genetic Testing for Rare Disorders of Obesity: Experience and Perspectives of Pediatric Weight Management Providers.

Childhood obesity (Print)·2024
Same journal

Exploring Communities: Use of Windshield Surveys in Pediatric Residency Education.

Clinical pediatrics·2026
Same journal

Utility of E-Nose in Paediatric Respiratory Diseases Using Machine Learning Approach: A Pilot Study.

Clinical pediatrics·2026
Same journal

Effect of Preferred Language on Pediatric Rapid Response Activation and Subsequent Intensive Care Utilization.

Clinical pediatrics·2026
Same journal

Documented Caregiver Report of Wheezing at Home is Associated With Decreased Length of Pediatric Asthma Hospitalizations.

Clinical pediatrics·2026
Same journal

The Rash That Will Not Go Away.

Clinical pediatrics·2026
Same journal

Virtual Reality Education for Hospitalized Pediatric Patients Improves Intrinsic Motivation: A Prospective, Randomized Crossover Study.

Clinical pediatrics·2026
See all related articles

Related Experiment Video

Updated: Jan 18, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.1K

Metformin Treatment: Pediatric Weight Management Experience.

Rand Hashim1,2, Adolfo J Ariza1,3, Helen J Binns1,3

  • 1Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.

Clinical Pediatrics
|January 16, 2026
PubMed
Summary
This summary is machine-generated.

Metformin may help non-diabetic youth with obesity improve weight status. This study found that youth taking metformin for at least six months showed the most significant weight improvements, with fewer side effects reported.

Keywords:
metforminpediatric obesityprediabetesside effectsweight management

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

909
Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

14.7K

Related Experiment Videos

Last Updated: Jan 18, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.1K
Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

909
Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

14.7K

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Health
  • Obesity Medicine

Background:

  • Obesity affects a significant number of non-diabetic youth.
  • Metformin is increasingly considered for pediatric weight management.
  • Evidence on long-term metformin efficacy and patient experience in this population is limited.

Purpose of the Study:

  • To evaluate patient-reported experiences with metformin in non-diabetic youth with obesity.
  • To assess the association between metformin use duration and changes in weight status.
  • To identify factors associated with metformin use in a pediatric weight management program.

Main Methods:

  • Retrospective review of 161 youth with obesity in a pediatric weight management program.
  • Categorization into three groups: metformin taken ≥6 months, <6 months, and ordered not taken.
  • Analysis of weight status changes and reported side effects.

Main Results:

  • All groups had similar baseline weight status.
  • Youth taking metformin ≥6 months had earlier initiation and higher rates of prediabetes and parental diabetes.
  • Overall weight status improvement was 57.1%, with the highest in the ≥6 months metformin group (69.0%).
  • 35.4% of those who took metformin reported side effects, with no significant group variation.

Conclusions:

  • Metformin use, particularly for ≥6 months, is associated with improved weight status in non-diabetic youth with obesity.
  • Patient-reported side effects were common but did not significantly differ by duration of use.
  • Metformin may be a valuable adjunct to lifestyle changes in pediatric weight management programs.